1. Home
  2. LYRA vs FRSX Comparison

LYRA vs FRSX Comparison

Compare LYRA & FRSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LYRA
  • FRSX
  • Stock Information
  • Founded
  • LYRA 2005
  • FRSX N/A
  • Country
  • LYRA United States
  • FRSX Israel
  • Employees
  • LYRA N/A
  • FRSX N/A
  • Industry
  • LYRA Medical/Dental Instruments
  • FRSX Computer Software: Prepackaged Software
  • Sector
  • LYRA Health Care
  • FRSX Technology
  • Exchange
  • LYRA Nasdaq
  • FRSX Nasdaq
  • Market Cap
  • LYRA 6.1M
  • FRSX 12.6M
  • IPO Year
  • LYRA 2020
  • FRSX 2017
  • Fundamental
  • Price
  • LYRA $0.11
  • FRSX $0.68
  • Analyst Decision
  • LYRA Hold
  • FRSX
  • Analyst Count
  • LYRA 4
  • FRSX 0
  • Target Price
  • LYRA $1.25
  • FRSX N/A
  • AVG Volume (30 Days)
  • LYRA 1.8M
  • FRSX 71.5K
  • Earning Date
  • LYRA 05-06-2025
  • FRSX 05-27-2025
  • Dividend Yield
  • LYRA N/A
  • FRSX N/A
  • EPS Growth
  • LYRA N/A
  • FRSX N/A
  • EPS
  • LYRA N/A
  • FRSX N/A
  • Revenue
  • LYRA $1,534,000.00
  • FRSX $436,000.00
  • Revenue This Year
  • LYRA N/A
  • FRSX N/A
  • Revenue Next Year
  • LYRA $237.15
  • FRSX N/A
  • P/E Ratio
  • LYRA N/A
  • FRSX N/A
  • Revenue Growth
  • LYRA N/A
  • FRSX N/A
  • 52 Week Low
  • LYRA $0.08
  • FRSX $0.55
  • 52 Week High
  • LYRA $5.65
  • FRSX $2.63
  • Technical
  • Relative Strength Index (RSI)
  • LYRA 42.33
  • FRSX 50.75
  • Support Level
  • LYRA $0.08
  • FRSX $0.60
  • Resistance Level
  • LYRA $0.10
  • FRSX $0.67
  • Average True Range (ATR)
  • LYRA 0.01
  • FRSX 0.06
  • MACD
  • LYRA 0.00
  • FRSX 0.01
  • Stochastic Oscillator
  • LYRA 62.16
  • FRSX 71.11

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

About FRSX Foresight Autonomous Holdings Ltd.

Foresight Autonomous Holdings Ltd is a technology company engaged in the design, development and commercialization of vision systems for the automotive industry. The company develops both in-line-of-sight vision systems and beyond-line-of-sight cellular-based applications through its wholly-owned subsidiaries. Its systems are designed to improve driving safety by enabling accurate and reliable threat detection while ensuring the lowest rates of false alerts. Foresight is pursuing several markets and believes its modern systems will revolutionize automotive safety by providing an automotive-grade, cost-effective platform.

Share on Social Networks: